| 摘要 |
FIELD: medicine, clinical immunology. SUBSTANCE: invention relates to development of the mixed vaccine containing hepatitis B virus antigen (HBsAg) obtained by culturing the transformed cells of S. cerevisiae, strain VKPM Y-2203, purified concentrated diphtheria anatoxin, purified concentrated tetanus anatoxin and whooping cough microbes killed with formalin and merthiolate, aluminium hydroxide gel and a pharmaceutically acceptable solvent also. EFFECT: decreased dose of hepatitis B virus antigen, enhanced immunological effectiveness of hepatitis, tetanus, diphtheria and whooping cough components in the mixed vaccine as compared with that of the separate preparations. 1 cl, 4 tbl |
